<DOC>
	<DOCNO>NCT01165684</DOCNO>
	<brief_summary>This trial conduct Europe , North South America . The aim clinical trial investigate two treatment equally effective .</brief_summary>
	<brief_title>Efficacy Safety Basal-bolus Therapy , Comparing Stepwise Addition Insulin Aspart Versus Complete Basal-bolus Regimen</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes ( diagnose clinically ) least 12 month Basal insulin treatment ( NPH twice daily , insulin glargine daily insulin detemir daily ) least 6 month HbA1c : 7.09.0 % ( inclusive ) central laboratory analysis ( one retest analyse central laboratory within week permit result last sample conclusive ) BMI ( Body Mass Index ) less 40.0 kg/m^2 Previous use premix bolus insulin ( allow previous use bolus insulin case hospitalisation severe condition require intermittent use bolus insulin le 14 consecutive day , last 6 month prior screen visit ( Visit 1 ) Use GLP1 ( Glucagonlike peptide1 ) receptor agonist pramlintide within last 6 month prior prior screen visit ( Visit 1 ) Anticipated change concomitant medication know interfere significantly glucose metabolism ( e.g . systemic corticosteroid , betablockers , MAO ( Monoamine oxidase ) inhibitor , etc . ) Cardiovascular disease , within last 12 month prior screen visit ( Visit 1 ) , define : stroke ; decompensated heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Uncontrolled treated/untreated severe hypertension ( systolic blood pressure sit least 180 millimetre ( mm ) mercury ( Hg ) and/or diastolic blood pressure least 100 mmHg ) . For Argentina : systolic blood pressure sit least 150 mmHg and/or diastolic blood pressure least 90 mmHg Impaired liver function , define ALAT ( Alanine aminotransferase ) least 2.5 time upper limit normal ( one retest analyse central laboratory within week permit result last sample conclusive ) Impaired renal function define serum creatinine 135 micromol/L ( 1.5 mg/dL ) males 110 micromol/L ( 1.2 mg/dL ) females ; , require locally applicable metformin label , glomerular filtration rate 60 ml/min , calculate Cockroft &amp; Gault formula ) . One retest within week permit result last sample conclusive Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic episode , last 12 month ) hypoglycaemic unawareness judge Investigator hospitalisation diabetic ketoacidosis previous 6 month Proliferative retinopathy maculopathy require treatment accord Investigator Treatment OADs ( Oral antidiabetic drug ) contraindicate unapproved combination treatment insulin ( accord local OAD label )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>